The Mincle-Activating Adjuvant TDB Induces MyD88-Dependent Th1 and Th17 Responses through IL-1R Signaling

Successful vaccination against intracellular pathogens requires the generation of cellular immune responses. Trehalose-6,6-dibehenate (TDB), the synthetic analog of the mycobacterial cord factor trehalose-6,6-dimycolate (TDM), is a potent adjuvant inducing strong Th1 and Th17 immune responses. We pr...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 1; p. e53531
Main Authors Desel, Christiane, Werninghaus, Kerstin, Ritter, Manuel, Jozefowski, Katrin, Wenzel, Jens, Russkamp, Norman, Schleicher, Ulrike, Christensen, Dennis, Wirtz, Stefan, Kirschning, Carsten, Agger, Else Marie, da Costa, Clarissa Prazeres, Lang, Roland
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 07.01.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0053531

Cover

More Information
Summary:Successful vaccination against intracellular pathogens requires the generation of cellular immune responses. Trehalose-6,6-dibehenate (TDB), the synthetic analog of the mycobacterial cord factor trehalose-6,6-dimycolate (TDM), is a potent adjuvant inducing strong Th1 and Th17 immune responses. We previously identified the C-type lectin Mincle as receptor for these glycolipids that triggers the FcRγ-Syk-Card9 pathway for APC activation and adjuvanticity. Interestingly, in vivo data revealed that the adjuvant effect was not solely Mincle-dependent but also required MyD88. Therefore, we dissected which MyD88-dependent pathways are essential for successful immunization with a tuberculosis subunit vaccine. We show here that antigen-specific Th1/Th17 immune responses required IL-1 receptor-mediated signals independent of IL-18 and IL-33-signaling. ASC-deficient mice had impaired IL-17 but intact IFNγ responses, indicating partial independence of TDB adjuvanticity from inflammasome activation. Our data suggest that the glycolipid adjuvant TDB triggers Mincle-dependent IL-1 production to induce MyD88-dependent Th1/Th17 responses in vivo.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Conceived and designed the experiments: CD KW RL. Performed the experiments: CD KW MR KJ NR JW. Analyzed the data: CD KW RL JW. Contributed reagents/materials/analysis tools: US DC SW CK EMA CPdC. Wrote the paper: CD MR CPdC RL.
Competing Interests: CAF01 is currently in clinical development at Statens Serum Institut and three clinical phase 1 studies have been conducted successfully. With regards to the intellectual property status on CAF01, the Statens Serum Institut has one issued patent (WO2006002642). None of the coauthors are registered as inventors on the patent and the full right has been transferred to Statens Serum Institut. EMA and/or DC are furthermore coinventors on patents on related technologies (WO2005004911A2, WO2009003474, WO2010054654, PCT/DK2012/000080) for all of which the full right has been transferred to Statens Serum Institut. This does not alter the authors’ adherence to the PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0053531